Adapthealth corp: Richard Cashin buys $4.4m in AHCO stock

Richard Cashin purchased 447,827 AdaptHealth (AHCO) shares for approximately $4.4M, bringing his direct and indirect holdings to 16,312,698 shares. AHCO reported Q4 2025 EPS of -$0.76 vs $0.36 consensus (a -311.11% surprise) while revenue beat at $846.3M vs $832.5M (+1.66%). RBC and Leerink maintained Outperform ratings with $13 and $12 price targets respectively; the stock trades at $10.37 (52-week high $11.17) and InvestingPro fair value is $13.78, implying potential upside despite noisy results and guidance concerns.

Analysis

Insider buying against a backdrop of noisy EPS prints and mixed guidance can be a signal that management expects operational remediation (bad-debt normalization, cost saves, inventory turns) to drive cash generation over the next 3–12 months. The market appears to be discounting near-term earnings volatility while implicitly assigning a lower multiple to the company’s recurring cash franchise; if margins rebase toward historical intermediate levels, a 20–40% multiple expansion is plausible without material top-line acceleration.

Key second-order pressures are reimbursement dynamics and working-capital swings. A small permanent cut to Medicare/Medicaid pricing or a sustained increase in receivable days would quickly compress free cash flow and force either debt-funded working-capital bridges or equity raises, amplifying downside. Conversely, simpler, faster wins (billing fixes, collection cadence, supply-chain cost-outs) can deliver outsized EPS leverage over 2–6 quarters because gross margin is highly operationally geared.

Catalysts to watch in the coming 30–180 days: company commentary on collections/DSO, cadence of equipment deliveries into peak respiratory season, and any pre-announcement around refinancing or covenant waivers. Tail risks include regulatory rule changes on durable-medical-equipment reimbursement and a near-term liquidity squeeze if covenant tests are missed; both would flip the trade from turnaround to distressed in a matter of weeks.

The consensus may be overweighting the one-off nature of the recent miss and underweighting the magnitude of operational leverage embedded in the business model. A disciplined, option-structured approach captures asymmetric upside if management execution improves while capping losses if macro/regulatory outcomes worsen.

Key Decisions for Investors

• Core directional: Buy AHCO shares sized 2–3% of portfolio for a 6–12 month horizon; target a 30–40% total return if margins normalize. Use a hard stop at -15% to limit capital loss from regulatory or liquidity shocks.
• Defined-risk upside: Enter a buy-call / sell-call spread to cap premium outlay — example structure: buy Oct‑2026 AHCO 10C / sell Oct‑2026 AHCO 16C (use strikes appropriate to market levels). Rationale: captures re-rating with limited cash outlay and defined max loss.
• Event hedge around next guidance/DSO update: Buy 4–6 week OTM puts (e.g., Jun‑2026 expiries) as cheap tail protection against a guidance downward revision or covenant event. Cost should be <1–2% of position notional to preserve asymmetric payoff.
• Tactical pair/short: If management signals need for equity/debt raise, initiate a short position (borrow) sized to risk tolerance with a 3–6 month horizon; target 20–40% downside in a dilution scenario. Pre-define max hold period and financing cost to avoid pinch during squeezes.